Faysal brings over 26 years of experience in pharmaceutical drug development and commercialization, including 21 years in portfolio management, R&D, and business development. He specializes in generics and biosimilars, with deep expertise in product portfolio strategy, IP assessments, valuations, and regulatory pathways such as ANDAs, 505(b)(2), and BLAs. Faysal has a strong track record in lifecycle management, Hatch-Waxman litigation strategy, and identifying first-to-file opportunities. His strengths include business intelligence, corporate strategy, and financial evaluation of licensing opportunities.

Faysal Kalmoua